secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prelude Therapeutics Inc (PRLD)
CIK:        0001678660
Form:       8-K
Filed at:   2026-05-12T11:11:58+00:00
Accession:  0001193125-26-218162
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prelude Therapeutics Q1 net loss $10.4M ($0.13/sh); cash runway into Q2 2028 after $90M offering
--------------------------------------------------------------------------------

- Net loss of $10.4M ($0.13 per share) vs $32.1M ($0.42) in Q1 2025; R&D spend fell to $13.6M.
- Cash, equivalents & securities of $84.8M at March 31; subsequent $90M offering extends runway to Q2 2028.
- Initiated Phase 1 trial of PRT12396, mutant-selective JAK2V617F inhibitor, in PV and MF patients.
- IND for KAT6A degrader PRT13722 expected by mid-2026; Phase 1 in ER+ breast cancer in 2H 2026.
- Appointed Charles Morris, M.D. as Chief Medical Officer in April 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/0001193125-26-218162-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1678660/000119312526218162/prld-20260512.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-218162

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer